News
Company news :quality(80))
ViruSure launches first GMP-validated viral safety test based on Oxford Nanopore sequencing
Company news :quality(80))
Singapore’s National Precision Medicine (NPM) programme engages Oxford Nanopore to advance understanding of the genetics of Singapore’s multi-ethnic p
Company news :quality(80))
Oxford Nanopore Technologies and UMC Utrecht collaborate on 1,000 human genome sequencing project
Technology :quality(80))
Oxford Nanopore opens genomics market with PromethION 2 Solo: the world’s first portable, high yield sequencer providing comprehensive DNA analysis for anyone, anywhere
Technology :quality(80))
Oxford Nanopore launches PromethION 2 Integrated into open early access
Company news :quality(80))
Oxford Nanopore at ASHG 2022: One sequencing platform for all your biology
Company news Oxford Nanopore and Genomics England announce new strategic research project to resolve undiagnosed rare disease cases
Interviews Interview: Using PromethION for Cancer, Collaborations and more
Interviews Interview: Sequencing the poplar with PromethION
Interviews Interview: The PromethION Experts at VIB
Interviews Interview: PromethION 24 and human disease research
Interviews Interview: Exploring complex disease in Asian populations with PromethION
Company news Innovations with ultra-long reads
Company news Blog: Resolving structural variants causing antithrombin deficiency
Company news Blog: cuteSV - a powerful tool to uncover the full spectrum of genomic structural variants
Company news :quality(80))
Al Jalila Children’s Hospital advances rare disease identification through Oxford Nanopore sequencing, a new study shows | Oxford Nanopore Technologies
